2,079 results for event

Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8452d55dbe493eb04186fd723085bf&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a825ee0f22843aa9759bdd92a5b6e5b&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84c9b4369d47ed9ea701c30b658523&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8435f89dc14db2ab4bfa4d2d07c25f&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a83654d3dcd439a8919c77063eb2a3e&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84506d462541e3b066d71a36116933&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a847aedb2a64834aaabee9b5e0b396b&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8246f204a94df1abeda6380816aa43&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a83950c2f144f5baa717d2248042da6&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a833bcfdb5a418e9f15a0bc9aebbb1a&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a839b5930d84386a2a1a5c6b2b23e37&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8303ec167748d0a9653455d96e3812&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a82c98ecf86493881531f28f301750c&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84554eb9e04454be4175bcee3cc392&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84cd25de6a4957be4e3ab4d127e293&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8474e5f839463699e121f666c262af&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a828a450bfe46509f6f46286aadfb91&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a824c6b6b104e9ba0425bf1c445db7b&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84e25cfb7749748a87d301d9304954&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84cee11a3c40a1aae82bf99b9edc80&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM